First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

Conditions: Locally Advanced/Metastatic Solid Tumors Interventions: Drug: FL115 Sponsors: Suzhou Forlong Biotechnology Co.,Ltd, Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials